Revenue

Phenomenex, a Danaher company, launches its Luna Omega HILIC columns, aiming to simplify complex analysis in pharma, food safety, and diagnostics.

Medtronic veteran Jesse Litwak joins ProVerum, a move signaling the BPH innovator is shifting from R&D to aggressive commercial scale-up with its new ProVee tech.

As the Pentagon scrambles for battle-tested autonomous weapons, a new partnership promises to deliver. But is fast-tracking foreign tech the answer or a risky bet?

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

Kymera Therapeutics' new lupus data isn't just about a drug. It's about a new strategy: erasing disease-causing proteins to build resilient value.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

With its new ISED-certified Private 5G portfolio for Canada's NCL band, Ontario's BLiNQ Networks is poised to drive industrial automation and smart city growth.

Beyond the blowout earnings, Optical Cable Corp's Q2 results reveal a playbook for thriving in the digital infrastructure boom. Here's the strategic rationale.

Calpine's new 25MW geothermal expansion at The Geysers provides baseload power for 25,000 homes, boosting California's grid and cementing Constellation's strategy.

Beyond the gridlock in Meriden lies a story of strategic ambition. A look at how Parsons' engineering and a massive state investment aim to redefine a vital corridor.

Trane Technologies' latest report shows it's not just cutting emissions but building a profitable business model around it. A deep dive into their strategy.

Following its acquisition by Pearl Street Equity, Famous Brands brings in Richard Screnci to apply his QSR playbook to the iconic dessert franchises.

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

A CPG veteran launches Lioness, a functional gummy snack for women. Can timed ingredients and a massive retail launch redefine the wellness market?

EQT appoints M&A mastermind Gustav Segerberg as CFO, signaling a doubling-down on its aggressive growth strategy. What does this mean for its future?

A Mumbai-based EdTech firm has assembled a team of global publishing and tech titans. This isn't just a board; it's a strategic play to write the rules for the AI-driven future of learning.

A new warehouse near DFW is more than just logistics. It's a calculated move to combat costly aircraft downtime and redefine the global parts supply chain.

New data reveals a silent crisis as 3 in 5 HR pros consider quitting. We explore the tech debt and leadership gaps pushing them to the brink.

Amai Proteins' sweelin® just got a major scientific boost. New clinical data in a top journal proves its metabolic safety, fast-tracking its commercial journey.